Ge P, Wang L, Lu M, Mao L, Li W, Wen R, et al. Oncological outcome of primary and secondary Muscle-Invasive bladder cancer: A systematic review and Meta-analysis. Sci Rep. 2018;8(1):7543. https://doi.org/10.1038/s41598-018-26002-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, et al. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol (EJSO). 2014;40(12):1738–45. https://doi.org/10.1016/j.ejso.2014.10.004.

Article  CAS  PubMed  Google Scholar 

Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391(10139):2525–36. https://doi.org/10.1016/S0140-6736(18)30996-6.

Article  PubMed  Google Scholar 

Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, et al. Standard or extended lymphadenectomy for Muscle-Invasive bladder Cancer. N Engl J Med. 2024;391(13):1206–16. https://doi.org/10.1056/NEJMoa2401497.

Article  PubMed  PubMed Central  Google Scholar 

Hahn NM, Sachse K, Schulman D, Sloan F, Quale DZ, Lotan Y, et al. Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs. J Clin Oncol. 2021;39(6suppl):424. https://doi.org/10.1200/JCO.2021.39.6_suppl.424.

Article  Google Scholar 

Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3(6 Suppl 4):S199–205. https://doi.org/10.5489/cuaj.1196.

Article  PubMed  PubMed Central  Google Scholar 

Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790–7. https://doi.org/10.1016/j.eururo.2006.01.017.

Article  PubMed  Google Scholar 

Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158(1):62–7. https://doi.org/10.1097/00005392-199707000-00017.

Article  CAS  PubMed  Google Scholar 

Davies BJ, Hwang TJ, Kesselheim AS. Ensuring access to injectable generic Drugs - The case of intravesical BCG for bladder Cancer. N Engl J Med. 2017;376(15):1401–3. https://doi.org/10.1056/NEJMp1615697.

Article  PubMed  Google Scholar 

Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, et al. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. BJU Int. 2022;130(3):323–30. https://doi.org/10.1111/bju.15661.

Article  PubMed  Google Scholar 

Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of Valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin study group. J Urol. 2000;163(3):761–7.

Article  CAS  PubMed  Google Scholar 

Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American urological association public workshop. Urology. 2014;83(2):262–4. https://doi.org/10.1016/j.urology.2013.10.030.

Article  PubMed  Google Scholar 

Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for Non-Muscle-Invasive bladder cancer: recommendations from the international bladder Cancer group. J Clin Oncol. 2016;34(16):1935–44. https://doi.org/10.1200/jco.2015.64.4070.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919–30. https://doi.org/10.1016/S1470-2045(21)00147-9.

Article  CAS  PubMed  Google Scholar 

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10(3):525–32. https://doi.org/10.1016/j.ymthe.2004.05.027.

Article  CAS  PubMed  Google Scholar 

Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene Firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–17. https://doi.org/10.1016/s1470-2045(20)30540-4.

Article  CAS  PubMed  Google Scholar 

Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, et al. IL-15 superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive bladder Cancer. NEJM Evid. 2023;2(1):EVIDoa2200167. https://doi.org/10.1056/EVIDoa2200167.

Article  PubMed  Google Scholar 

Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage Colony-Stimulating Factor–Armed oncolytic adenovirus for the treatment of bladder Cancer. Clin Cancer Res. 2006;12(1):305–13. https://doi.org/10.1158/1078-0432.Ccr-05-1059.

Article  CAS  PubMed  Google Scholar 

Tyson MDUE, Nam JK, Lamm DL, Bivalacqua TJ, Shore ND. Single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk. A Phase 3, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Journal of Urology [Internet]. 2024(211).

Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol. 2004;172(1):70–5. https://doi.org/10.1097/01.ju.0000132129.87598.3b.

Article  PubMed  Google Scholar 

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5. https://doi.org/10.1016/j.eururo.2005.12.031. discussion 75– 7.

Article  PubMed  Google Scholar 

Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, et al. Bladder-Preserving trimodality treatment for High-Grade T1 bladder cancer: results from phase II protocol NRG oncology/rtog 0926. J Clin Oncol. 2024;42(34):4095–102. https://doi.org/10.1200/jco.23.02510.

Article  CAS  PubMed  Google Scholar 

Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378–88. https://doi.org/10.18632/oncotarget.16386.

Article  PubMed  PubMed Central  Google Scholar 

Clements MB, Atkinson TM, Dalbagni GM, Li Y, Vickers AJ, Herr HW, et al. Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol. 2022;81(3):294–304. https://doi.org/10.1016/j.eururo.2021.09.018.

Article  PubMed  Google Scholar 

Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013;112(1):13–25. https://doi.org/10.1111/j.1464-410X.2012.11762.x.

Article  PubMed  Google Scholar 

Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving Tri-modality therapy for patients with Muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol. 2017. https://doi.org/10.1016/j.eururo.2016.12.020.

Article  PubMed  Google Scholar 

Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99– 06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, Paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7. https://doi.org/10.1016/j.urology.2008.09.036.

Article  PubMed  Google Scholar 

James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. https://doi.org/10.1056/NEJMoa1106106.

Article  CAS  PubMed  Google Scholar 

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN guidelines® insights: bladder cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2024;22(4):216–25. https://doi.org/10.6004/jnccn.2024.0024.